DaTSCAN Imaging in Aging and Neurodegenerative Disease
Status:
Enrolling by invitation
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The investigators propose using DaTscan in patients with REM sleep behavior disorder (RBD),
mild cognitive impairment (MCI), Parkinson's disease (PD), dementia with Lewy bodies (DLB),
Alzheimer's disease (AD), and other neurodegenerative syndromes and disorders, to test
several hypotheses - some confirmatory, and some novel. Such use will provide new data on the
potential clinical and research utility of DaTscan in neurodegenerative diseases. The
findings on DaTscan will be correlated with clinical diagnoses and other multimodal imaging
studies (e.g., MRI, MRS, FDG-PET, and amyloid-PET) to enhance our understanding of
neurodegenerative diseases.